TWSTTwist Bioscience Corporation
Is it safe?
Solid, nothing alarming: clean books, but heavy debt (CCC) and big price swings.
Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Insiders were net sellers (-$119.6M, 90 days to Oct 8, 2026), selling is often routine.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -94% · now 22% below its 52-week high.
Unless marked, from SEC EDGAR, as of Sep 30, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can TWST take a bad year?
The deepest fall in TWST's price history on file is −94%; it is 22% below its high today.
Worst drawdown on file · −22% today
- Cash runway
- 1.8 years
Cash runway · burning $23M a quarter at the current rate
- Annualised volatility
- 72%
Annualised volatility · three times the market's own swing
Details›
- Cash and short-term investments
- $167M
- EBITDA, trailing twelve months
- −$120M
- Operating profit, trailing twelve months
- −$145M
- Annualised volatilitytwo years of daily moves
- 72%
- Worst drawdown on file
- −94%
- Below its 52-week high
- 22%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Diagnostics & Research
Ranks #20 of 21 by RyuScore